The Pharma LetterCell and Gene Therapy Catapult enters Japanese collaborationThe Pharma LetterThe UK government-backed Cell and Gene Therapy Catapult (CGT Catapult) today announced it has signed a Memorandum of Understanding (MoU) with the Japanese Soc… Continue reading
GlobeNewswire (press release)Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 …GlobeNewswire (press release)CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) — Intellia Therapeutics, … Continue reading
OncLive |
Hepatocellular Carcinoma: Future Role of Immunotherapy
OncLive Ghassan Abou-Alfa, MD: While we’re getting all those great results from checkpoint inhibitors, as we just discussed, you already have nivolumab onboard, you have pembrolizumab onboard, and you have durvalumab and tremelimumab in combination onboard … |
physicsworld.com |
Biofabrication
physicsworld.com Two years on from Groll and colleagues’ reappraisal, biofabrication can be found describing the generation of nanostructured assemblies containing biological materials. And updating the picture further, subsets of the broader field also include uses in … |
FierceBiotech |
Generation Bio raises $100M for ‘druglike’ gene therapy
FierceBiotech Gene therapy startup Generation Bio has lost no time raising the resources it needs to take its programs forward into the clinic, closing a $100 million second-round financing just over a month after its $25 million Series A. The Atlas Venture-backed … Fresh Off $25M Raise, Generation Adds $100M For Next-Gen Gene TherapyXconomy Hauling in a $100M mega-round, gene therapy startup Generation Bio builds alternative to potentially risky viral vectorsEndpoints News Redosable Gene–Therapy Developer Generation Bio Wins $100M Series B FinancingGenetic Engineering & Biotechnology News Boston Business Journal –Business Wire (press release) all 7 news articles » |